Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

The Department of Defense (DOD) Uniform Formulary Class is seeking quotes for ANTIHYPERTENSIVE AGENTS, with quotes due by January 5, 2026, for a P&T Committee Meeting on February 4-5, 2026. The document details requirements for both Blanket Purchase Agreement (BPA) and Additional Discount Program (ADP) appendices. Manufacturers are instructed to submit fully executed signature pages with their quote information. The P&T Committee will review these agents in accordance with 32 CFR 199.21(g)(5), potentially applying Prior Authorization and considering tier designations, including preferential status for non-generic agents as Tier 1. Agents with unsubmitted or unselected Request For Quote (RFQ) may be designated non-step preferred. The file emphasizes that the price per unit of measure will be consistent across all package sizes within a given dispensing venue for BPA, and details refund calculations based on Federal Ceiling Price (FCP) and Wholesale Acquisition Cost (WAC) for the ADP.

The Department of Defense (DOD) Uniform Formulary Class for Oncological Agents outlines the process for evaluating and managing newly approved drugs. Quotes for these agents are due by January 5, 2026, with the Pharmacy & Therapeutics (P&T) Committee meeting scheduled for February 4-5, 2026. The document details two main appendices: the Blanket Purchase Agreement (BPA) Appendix and the Additional Discount Program (ADP) Appendix. Both appendices require manufacturers to submit quotes for Uniform Formulary and Non-Formulary drugs, as well as for Tier 2 and Tier 3 TRICARE Retail Refund scenarios. The P&T Committee will review these agents according to 32 CFR 199.21(g)(5), considering factors like prior authorization, generic agent step therapy, and potential for special reimbursement methods to encourage high-value products. Manufacturers are reminded to submit fully executed signature pages with their quote information. The document also specifies that the price per unit of measure will be consistent across all package sizes and details how refunds are calculated based on Federal Ceiling Price (FCP) and Wholesale Acquisition Cost (WAC).

The Department of Defense (DOD) Uniform Formulary Class for DIURETICS is undergoing review, with a P&T Committee Meeting scheduled for February 4-5, 2026. Quotes for both Blanket Purchase Agreement Appendix and Additional Discount Program for newly approved drugs were due by January 5, 2026. This document outlines the requirements and conditions for pharmaceutical manufacturers, emphasizing the submission of fully executed signature pages along with quote information. The P&T Committee will review these agents according to 32 CFR 199.21(g)(5) and may implement Prior Authorization (PA), consider tier designation for drugs without existing brands, and identify candidates for special reimbursement or exclusion from the TRICARE pharmacy benefit. The price per unit for a given dosage form and strength must be consistent across all package sizes within a dispensing venue. For the Additional Discount Program, details regarding TRICARE Retail Refund, Federal Ceiling Price (FCP), non-FAMP, and Wholesale Acquisition Cost (WAC) calculations are provided, with an emphasis on the static nature of the quoted additional refund and WAC discount percentages throughout the agreement.

This document outlines instructions for completing price appendices related to federal government RFPs, specifically for Blanket Purchase Agreements (BPAs) and Average Discount Price (ADP) calculations (both non-FAMP and WAC discounts). The guidelines emphasize reading Formulary Notes for P&T committee decision-making, filling in only yellow cells, and understanding auto-calculation features for package size, price per unit, and refund amounts. It details how to indicate a refusal to quote for a condition set or formulary category, which is typically shown by a red highlight when specific cells are left blank or zero values are entered. The document also specifies that tables are provided for 10 NDCs, but vendors only need to fill out relevant tables, and additional tables can be requested from POCs on the RFQ document. Contact information for questions or concerns is also provided.

The Defense Health Agency issued Amendment 0001 to Solicitation HT9402-26-Q-9103 on December 17, 2025. This amendment specifically updates the Komzifti price list by revising the classification for certain agents. The class/subclass was changed from "Oncological Agents - N/A" to "Leukemia and Lymphoma Agents - Acute Myelogenous Leukemia." All other terms and conditions of the original solicitation remain unchanged. The amendment was digitally signed by Marsha L. Petersen, the Contracting Officer, indicating an official modification to the solicitation document.

The Department of Defense (DOD) Uniform Formulary Class for Leukemia and Lymphoma Agents, specifically for Acute Myelogenous Leukemia, is preparing for a P&T Committee Meeting on February 4-5, 2026. The deadline for submitting quotes is January 5, 2026. The document outlines requirements for both Blanket Purchase Agreements (BPAs) and an Additional Discount Program (ADP) for newly approved drugs. Manufacturers are required to submit fully executed signature pages along with quote information. The P&T Committee will review these agents, considering factors like Prior Authorization, generic agent inclusion, potential tier designations, and special reimbursement methods to encourage high-value products. Agents not submitted or selected may be designated as non-step preferred. The document also details the calculation of retail refunds based on Non-FAMP and Federal Ceiling Price (FCP), and for products without FCP, the Wholesale Acquisition Cost (WAC) is used.

The Department of Defense (DOD) Defense Health Agency (DHA) is issuing a Request for Quotation (RFQ) for pharmaceutical agents to be included on the Uniform Formulary (UF). This RFQ outlines the process for manufacturers to submit offers for Blanket Purchase Agreements (BPAs) for Military Treatment Facilities (MTFs) and TRICARE Mail Order Pharmacy (TMOP), and Additional Discount Program (ADP) agreements for TRICARE retail network pharmacies. The DOD Pharmacy and Therapeutics (P&T) Committee will evaluate submissions based on clinical and cost-effectiveness, classifying agents into generic, formulary, or non-formulary tiers. The RFQ includes a submission checklist, outlines the evaluation criteria, and details the requirements for pricing and refund quotes, emphasizing legal compliance and the importance of accurate National Drug Code (NDC) price lists. Key dates for teleconferences, quote submissions, and committee meetings are provided, along with contact information for various points of contact.

The Department of Defense (DOD) Uniform Formulary is seeking quotes for lung cancer drugs, specifically for the HER2+ subclass, to be reviewed at the P&T Committee Meeting on February 4-5, 2026. Quotes are due by January 5, 2026. The Request for Quote (RFQ) includes provisions for both Uniform Formulary and Non-Formulary drugs, with "NO QUOTE" indicated for various National Drug Code (NDC) numbers across multiple scenarios. Manufacturers are reminded to submit fully executed signature pages along with their quote information. The P&T Committee may apply Prior Authorization, consider tier designations for agents without existing brands, and evaluate drugs for special reimbursement methods to encourage high-value products. They may also recommend preferential status (Tier 1) for non-generic agents or complete exclusion from the TRICARE pharmacy benefit program. Agents without submitted or selected RFQs may be designated "non-step preferred." The document also outlines the Additional Discount Program, including TRICARE Retail Refund scenarios for Tier 2 and Tier 3 drugs, and details regarding the calculation of total retail refunds based on Federal Ceiling Price (FCP) and Wholesale Acquisition Cost (WAC) discounts.

The document outlines the Department of Defense (DOD) Uniform Formulary and Additional Discount Program Appendices for ANTILIPIDEMICS-2, scheduled for review at the P&T Committee Meeting on February 4-5, 2026, with quotes due by January 5, 2026. It details the process for newly approved drugs, specifying NDC numbers for "Uniform Formulary" and "Non-Formulary" scenarios in the Blanket Purchase Agreement Appendix, and "Tier 2" and "Tier 3" in the Additional Discount Program Appendix for TRICARE Retail Refunds. Manufacturers are reminded to submit executed signature pages with quotes. The document emphasizes that the P&T Committee will review these agents, potentially applying Prior Authorization (PA), considering tier designations for brand-absent agents, and recommending special reimbursement methods or exclusions from the TRICARE pharmacy benefit. Pricing for the Blanket Purchase Agreement Appendix will be uniform across package sizes within a dispensing venue, while the Additional Discount Program Appendix details the calculation of retail refunds based on Federal Ceiling Price (FCP) and Wholesale Acquisition Cost (WAC) where FCP is unavailable.

The Department of Defense (DOD) is issuing a Request for Quotation (RFQ) for drugs within the TARGETED IMMUNOMODULATORY BIOLOGICS class, specifically the INTERLEUKIN 23 subclass. Quotes are due by January 5, 2026, for the P&T Committee Meeting on February 4-5, 2026. The RFQ includes a Blanket Purchase Agreement Appendix for newly approved drugs and an Additional Discount Program Appendix. Manufacturers are required to submit fully executed signature pages along with quote information. The document outlines various formulary scenarios, including "Uniform Formulary Before Step Therapy," "Uniform Formulary After Step Therapy," and "Non-Formulary After Step Therapy" for Military Treatment Facilities and Mail Order, as well as Tier 2 and Tier 3 scenarios for TRICARE Retail Refund. Prior Authorization (PA) may apply, and agents may be considered for special reimbursement or preferential status. The P&T Committee will evaluate removing step preferences for certain indications, and agents without submitted or selected RFQs may be designated non-step preferred. The document also details the calculation of retail refunds based on Federal Ceiling Price (FCP) and Wholesale Acquisition Cost (WAC) discounts, emphasizing the dynamic nature of these prices and the static nature of the quoted discount percentages.

The DoD Final Rule, effective August 26, 2015, outlines the process for formulary placement of newly approved innovator drugs within the TRICARE Pharmacy Benefits Program. The Pharmacy and Therapeutics (P&T) Committee has up to 120 days to recommend tier placement for FDA-approved medications, including new molecular entities, active ingredients, dosage forms, and combinations. Drugs approved on or after the effective date are initially assigned a pending status and treated as non-formulary. The DHA Director holds final approval authority for P&T Committee recommendations. Cost-effectiveness is evaluated using available pricing and solicited quotes from manufacturers, with drugs designated as Tier 1, 2, 3, or 4/Not Covered based on clinical and cost data. Innovator drugs are typically Tier 3 and only available at military treatment facilities or with Tier 2 copay through other pharmacies if medical necessity criteria are met.